AI Scribes in SEA Face Regulatory and Partnership Hurdles

Medical artificial intelligence scribe startups operating in Southeast Asia are confronting significant regulatory barriers and partnership risks that threaten their market viability, according to a Tech in Asia report. The challenges range from multilingual consultation environments to strict data consent requirements that vary by country, complicating the deployment of AI tools designed to reduce doctor burnout.

Partnership Risk: The Amazon Basics Playbook

Startups bringing AI scribes to Southeast Asia are navigating a familiar tech industry pattern. AI scribe company Abridge partnered with Epic, the dominant electronic medical records (EMR) provider in the United States, in 2023 to accelerate hospital adoption. Two years later, Epic announced it was building its own AI scribe with Microsoft. The tool went live in February 2026, transforming Abridge’s strategic partner into direct competition.

As noted in the source material, “Working with EMR providers is the fastest way to onboard hospitals. The bigger the partner, however, the more likely they are to eventually build what these startups are selling.” This dynamic creates a dilemma for SEA-based startups: partnering with major EMR providers offers rapid scaling but risks eventual displacement.

Regulatory and Linguistic Barriers

Beyond partnership concerns, regulatory and linguistic complexity adds another layer of difficulty. In Indonesia, doctors frequently switch between Indonesian and regional languages such as Sundanese or Javanese during patient consultations. This multilingual environment creates accuracy concerns for local medical AI scribes, limiting adoption despite the technology’s promise.

Vietnam presents a different regulatory obstacle. The country’s law requires doctors to obtain written patient consent each time an AI scribe tool is used—a requirement that cannot be easily resolved through technological advancement alone. According to the source, “It’s the kind of obstacle that can’t be cleared easily by just advancing the tech.”

Market Growth Despite Headwinds

Despite these barriers, adoption of medical AI scribes is growing in the region, though the path remains narrower than it appears. Doctor burnout remains a genuine problem that these tools are designed to address, but whether startups solving this problem will retain their business models remains uncertain.

Related Context: Grab’s Financial Performance and AI Strategy

In parallel developments within Southeast Asia’s tech ecosystem, Grab reported strong Q1 financial results, with revenue rising 24% year over year to US$955 million. The super app’s on-demand gross merchandise value also increased 24% year over year to US$6.1 billion. Most notably, Grab’s gross loan portfolio grew 130% year over year to US$1.4 billion, with total loans disbursed reaching an all-time high of US$1.1 billion in the quarter.

Grab’s financial services growth stems from both GrabFin and its digibanks in Singapore and Malaysia. The company has emphasized AI as a growth driver, with CEO Anthony Tan discussing “leaning deeply into AI” in the company’s latest earnings letter. In 2024, Grab conducted a notable strategic pause, halting its entire engineering team’s shipping of new features for nine weeks—with no new features or growth targets—to develop AI capabilities at scale.